FDA Approves Otarmeni™ as First Gene Therapy for Genetic Hearing Loss
Recently, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Otarmeni
(lunsotogene parvec-cwha). This marks a significant milestone as it becomes the first gene therapy approved for treating genetic hearing loss, specifically severe-to-profound OTOF-related hearing loss.
About Otarmeni: A Revolutionary Advancement in Hearing Loss Treatment
Otarmeni is an innovative gene therapy designed for both pediatric and adult patients suffering from profound sensorineural hearing loss linked to confirmed mutations in the OTOF gene. This therapy utilizes an adeno-associated virus vector to deliver a functional copy of the OTOF gene directly into the inner ear.
The FDA’s approval is based on promising results from the pivotal CHORD trial. In this study, 80% of participants demonstrated significant improvements in hearing sensitivity. With further follow-up, 42% of participants even achieved normal hearing, including the ability to hear whispers.
Key Findings from the CHORD Trial
- Participants aged 10 months to 16 years received a single dose via intracochlear infusion.
- 80% experienced hearing improvements, reaching the trial’s primary endpoint. This was noted as a threshold of ≤70 dB HL, which often allows for natural hearing without cochlear implants.
- 70% showed auditory brainstem responses at ≤90 dB, confirming significant auditory function.
- By week 48, all initial responders maintained their improvements, with 42% attaining normal hearing levels.
The CHORD trial involved 20 participants who underwent either unilateral or bilateral treatment. This therapy represents a groundbreaking shift for families affected by a condition previously deemed permanently debilitating.
Otarmeni: Accessibility and Future Implications
Regeneron Pharmaceuticals, the developer behind Otarmeni, is committed to making this therapy available at no cost for eligible patients in the U.S. While the therapy itself is provided for free, associated out-of-pocket costs may exist, and individuals should consult health insurance providers for specifics.
Recent research highlights that OTOF-related hearing loss is exceedingly rare, impacting about 50 infants each year in the United States. The condition stems from faulty OTOF gene variants, which result in the lack of otoferlin protein vital for effective auditory communication.
Expert Insights on the Approval
According to Dr. A. Eliot Shearer, an otolaryngologist involved in the CHORD trial, Otarmeni opens a new chapter in treating genetic hearing loss. He noted that children have achieved remarkable improvements, able to interact and engage with sound in ways previously unattainable.
George D. Yancopoulos, Chief Scientific Officer at Regeneron, expressed pride in the company’s groundbreaking contribution to genetic medicine. The treatment not only enhances scientific boundaries but also embodies Regeneron’s commitment to serving the greater good.
Conclusion
The accelerated approval of Otarmeni as the first gene therapy for OTOF-related hearing loss heralds new possibilities for those affected. It exemplifies the potential for gene therapies to transform lives, allowing individuals to experience the world with full auditory capabilities.
For further information, individuals interested in Otarmeni can reach out to Regeneron’s dedicated support program at 1-866-500-GENE (1-866-500-4363).
